Avram Denburg

University of Toronto

Canada

This profile is automatically generated from trusted academic sources.

Google Scholar

.

ORCID

.

LinkedIn

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI

Contact this professor

LinkedIn

Google Scholar

Research Interests

Health Economics

50%

Pharmacotherapy

60%

Evidence-based Medicine

40%

Pharmacoeconomics

30%

Pediatric Oncology

30%

Comparative Effectiveness Research

20%

Clinical Decision Making

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles11

Institutional Priority-Setting for Novel Drugs and Therapeutics: A Qualitative Systematic Review

Year:

2024

Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration

Year:

2023

Prevention of treatment abandonment in sub‐Saharan Africa; Lessons learned in Malawi that guide the way forward to cost‐effective interventions: A report from CANCaRe Africa

Year:

2023

Translating Precision Health for Pediatrics: A Scoping Review

Year:

2023

Evaluation of a Health Care Worker Training Intervention to Improve the Early Diagnosis and Referral of Childhood Cancers in Ghana: A Qualitative Descriptive Study

Year:

2022

What’s in a Name? Parents’ and Healthcare Professionals’ Preferred Terminology for Pathogenic Variants in Childhood Cancer Predisposition Genes

Year:

2022

Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey

Year:

2022

Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group

Year:

2022

Childhood cancer drugs in China: An overview and comparison of regulatory approvals in China and the United States

Year:

2022

Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise

Year:

2021

Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group

Year:

2021

Collaborators2

Sumit Gupta

University of Toronto

CANADA

Stuart Peacock

Professor

Simon Fraser University

CANADA

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI